Biogen Idec Inc. - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 102 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Biogen Idec Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Biogen Idec Inc. - Product Pipeline Review - 2014', provides an overview of the Biogen Idec Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biogen Idec Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biogen Idec Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biogen Idec Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Biogen Idec Inc.'s pipeline products

Reasons to buy

- Evaluate Biogen Idec Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biogen Idec Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biogen Idec Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biogen Idec Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biogen Idec Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biogen Idec Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Biogen Idec Inc. Snapshot 7
Biogen Idec Inc. Overview 7
Key Information 7
Key Facts 7
Biogen Idec Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Biogen Idec Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Biogen Idec Inc. - Pipeline Products Glance 18
Biogen Idec Inc. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Biogen Idec Inc. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Biogen Idec Inc. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Biogen Idec Inc. - Drug Profiles 24
coagulation factor IX-Fc (recombinant) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
coagulation factor VIII-Fc (recombinant) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dimethyl fumarate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
natalizumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
peginterferon beta-1a 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BG-00010 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BIIB-023 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BIIB-033 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
rituximab 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
STX-100 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
aducanumab 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BG-00001 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BIIB-059 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BIIB-061 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
5D-10 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Antibodies to Inhibit Alpha Synuclein for Neurodegenerative Diseases 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BIIB-034 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BIIB-053 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BIIB-054 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drug to Modulate Gamma Secretase for Alzheimer Disease 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NI-105 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Interleukin-34 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Recombinant Macrophage Colony Stimulating Factor 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
TDP-43 Program 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules for Parkinsons Disease 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Biogen Idec Inc. - Pipeline Analysis 58
Biogen Idec Inc. - Pipeline Products by Target 58
Biogen Idec Inc. - Pipeline Products by Route of Administration 61
Biogen Idec Inc. - Pipeline Products by Molecule Type 62
Biogen Idec Inc. - Pipeline Products by Mechanism of Action 63
Biogen Idec Inc. - Recent Pipeline Updates 66
Biogen Idec Inc. - Dormant Projects 86
Biogen Idec Inc. - Discontinued Pipeline Products 89
Discontinued Pipeline Product Profiles 89
baminercept alfa 89
clenoliximab 89
CNF-1010 89
dexpramipexole dihydrochloride 89
naxifylline 89
vipadenant 90
Biogen Idec Inc. - Company Statement 91
Biogen Idec Inc. - Locations And Subsidiaries 96
Head Office 96
Other Locations & Subsidiaries 96
Biogen Idec Inc. - Key Manufacturing Facilities 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102

List of Tables
Biogen Idec Inc., Key Information 7
Biogen Idec Inc., Key Facts 7
Biogen Idec Inc. - Pipeline by Indication, 2014 9
Biogen Idec Inc. - Pipeline by Stage of Development, 2014 11
Biogen Idec Inc. - Monotherapy Products in Pipeline, 2014 12
Biogen Idec Inc. - Partnered Products in Pipeline, 2014 13
Biogen Idec Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Biogen Idec Inc. - Out-Licensed Products in Pipeline, 2014 16
Biogen Idec Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
Biogen Idec Inc. - Pre-Registration, 2014 18
Biogen Idec Inc. - Phase III, 2014 19
Biogen Idec Inc. - Phase II, 2014 20
Biogen Idec Inc. - Phase I, 2014 21
Biogen Idec Inc. - Preclinical, 2014 22
Biogen Idec Inc. - Discovery, 2014 23
Biogen Idec Inc. - Pipeline by Target, 2014 59
Biogen Idec Inc. - Pipeline by Route of Administration, 2014 61
Biogen Idec Inc. - Pipeline by Molecule Type, 2014 62
Biogen Idec Inc. - Pipeline Products by Mechanism of Action, 2014 63
Biogen Idec Inc. - Recent Pipeline Updates, 2014 66
Biogen Idec Inc. - Dormant Developmental Projects,2014 86
Biogen Idec Inc. - Discontinued Pipeline Products, 2014 89
Biogen Idec Inc., Other Locations 96
Biogen Idec Inc., Subsidiaries 96
Biogen Idec Inc., Key Manufacturing Facilities 100